Bone Resorption, Osteoclastogenesis and Adalimumab

Sponsor
Université de Sherbrooke
Study ID
NCT00814866
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    Adalimumab 40 mg sub-cutaneously every two weeks

Study Details

Osteoclastic bone resorption depends on both the capacity to generate osteoclasts (osteoclastogenesis) and on individual osteoclast activity. The investigators objective is to study the effect of anti-TNF therapy on the number of osteoclast precursors in the peripheral blood of patients with Rheumatoid Arthritis, on in vitro osteoclastogenesis and on osteoclast activity before and during the treatment of patients with Rheumatoid Arthritis with Adalimumab.

Key Dates

Start date
Sep 30, 2008
Status verified
Dec 2013
Primary completion
Sep 30, 2010
Completion
Mar 31, 2011

Study Design

Enrollment
28 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Other: Adalimumab
    Open label

Primary Outcome Measure

The number of osteoclast precursor (CD14+) cells in the peripheral blood [ Time Frame: 0, 3 and 6 months ]

Related Studies